TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1701802
Drug: Intermittent block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent block therapy with recombinant interferon gamma (4 X 10(6) I.U. daily, 4 cycles of 5 injections on days 1, 3, 5, 7, and 9)
Study: 1701802
Drug: Intermittent single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent single-dose therapy with recombinant interferon gamma (4 X 10(6) I.U. daily, 6 cycles of 1 injection on day 1)
Study: 6988175
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg nitrofurantoin plus 150 mg sulphadiazine 3-times daily
Study: 6988175
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg nitrofurantoin plus 500 mg sulphadiazine 3-times daily
Study: 6988175
Drug: Lower dosage
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dosage group (50 mg nitrofurantoin plus 150 mg sulphadiazine)
Study: 31176392
Drug: Modified SAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified SAE implants (test group)
Study: 31176392
Drug: SAE implants
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SAE implants (control group)
Study: 25586372
Drug: i-gel prewarmed
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel prewarmed to 42°C (W group)
Study: 25586372
Drug: i-gel kept
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel kept at room temperature (C group)
Study: 22181693
Drug: Topical Terbinafine
Normalized name: terbinafine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Terbinafine Nail Solution (TNS)
Study: 20002088
Drug: Warfarin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (10 mg)
Study: 20002088
Drug: Cocktail of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocktail of all five drugs
Study: 17155989
Drug: Treatment Preference
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Preference
Study: 2502251
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution containing L-alanine and glucose
Study: 2502251
Drug: Standard glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard glucose based oral rehydration solution
Study: 30551161
Drug: Long-term monitoring
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term monitoring (3-monthly urinalysis)
Study: 23596809
Drug: Xiaoaiping Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaoaiping Injection (XAP) plus best supportive treatment (BST)
Study: 23596809
Drug: Best supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best supportive treatment (BST)
Study: 22005564
Drug: Western therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western therapy + Modified Liang‐Ge San (group L)
Study: 22005564
Drug: Western therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western therapy only (group X)
Study: 16915119
Drug: Intra-arterial reteplase
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial reteplase (0.5, 1, 1.5, and 2 units) and intravenous abciximab (0.25 mg/kg bolus followed by 0.125 mg/kg/min)
Study: 16915119
Drug: Intra-arterial reteplase
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial reteplase and intravenous abciximab
Study: 14669038
Drug: i.m. corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. corticosteroid injection
Study: 23946326
Drug: varenicline (1mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: varenicline (1mg, twice per day for 12 weeks)
Study: 22498504
Drug: Preservative-free levocabastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free levocabastine 0.05% ophthalmic solution
Study: 22498504
Drug: Preserved levocabastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preserved levocabastine 0.05% ophthalmic suspension
Study: 17717030
Drug: Cinacalcet (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (25 mg/day titrated up to 100 mg/day)
Study: 11008927
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium supplements for 1 year
Study: 11008927
Drug: Low erythrocyte
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low erythrocyte magnesium levels (< 2.3 mmol/L)
Study: 6313557
Drug: Group I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I: local tumor irradiation (approximately 4,000 cGy) combined with 'one-time' irradiation of the upper and lower half of the body, midplane dose averaging 880 cGy.
Study: 6313557
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: two half-body irradiation treatments through anterior-posterior fields, average dose of 800 cGy given in two fractions (600 and 200 cGy).
Study: 20055782
Drug: Erdosteine (5-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine (5-8 mg/kg/day)
Study: 18807725
Drug: Bee-venom therapy
Normalized name: honey bee venom
DrugBank: Apis mellifera venom (DB10955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bee-venom therapy combined with Methotrexate, Sulfasalazine, and Meloxicam (3 months treatment)
Study: 18807725
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (Methotrexate, Sulfasalazine, Meloxicam)
Study: 19366302
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (Levemir)
Study: 10797151
Drug: DS of
Normalized name: l-alkaloids of belladonna
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS of 600 ml
Study: 19284179
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of valerian
Study: 11156086
Drug: Thoracoscopic, internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracoscopic, internal intercostal nerve block with 3 cc of 0.5% bupivacain at T2, T3, and T4 intercostal levels
Study: 9362354
Drug: Aprotinin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (2 x 10(6) KIU initially, followed by 5 x 10(5) KIU/h infusion)
Study: 19143194
Drug: Amlodipine (normodipine)
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine (normodipine) administered as monotherapy for 12 weeks
Study: 15814391
Drug: Transcervical Foley
Normalized name: CATHETER,FOLEY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcervical Foley catheters (Size 16F, 30 ml balloon)
Study: 10492406
Drug: Ropivacaine (8.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (8.0 ml of 1.0% ropivacaine with 50 IU/ml hyaluronidase)
Study: 10492406
Drug: Bupivacaine (8.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (8.0 ml of 0.75% bupivacaine with 50 IU/ml hyaluronidase)
Study: 1706910
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (84 micrograms administered in each nostril twice a day for 7 days)
Study: 1706910
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered in each nostril twice a day for 7 days)
Study: 31152545
Drug: Aronia whole
Normalized name: Aronia arbutifolia whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aronia whole fruit powder (12 mg, 10 g berries)
Study: 31152545
Drug: Aronia extract
Normalized name: Aronia melanocarpa fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aronia extract powder (116 mg, 75 g berries)
Study: 26431983
Drug: ID 15
Normalized name: THYROID 15MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID 15 μg HA
Study: 26431983
Drug: ID 6
Normalized name: isoniazid 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID 6 μg HA
Study: 26431983
Drug: ID 9
Normalized name: Myeloid 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID 9 μg HA
Study: 26431983
Drug: SC 15
Normalized name: Univasc 15mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC 15 μg HA
Study: 26431983
Drug: ID 15
Normalized name: THYROID 15MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID 15 μg HA (single or two doses)
Study: 26431983
Drug: SC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC vaccine
Study: 17389293
Drug: Web-based proactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based proactive system (PRECARES) with 2 monthly letters and follow-up calls
Study: 11865836
Drug: Pentoxifylline (PXF;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (PXF; 400 mg, 3 times daily)
Study: 10529021
Drug: Hydromorphone (HYD)
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone (HYD) 0 mg
Study: 10529021
Drug: Hydromorphone (HYD)
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone (HYD) 4 mg
Study: 10529021
Drug: Hydromorphone (HYD)
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone (HYD) 8 mg
Study: 10529021
Drug: Hydromorphone (HYD)
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone (HYD) 16 mg
Study: 7773850
Drug: Antifungal denture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal denture soaking solution (48 mL nystatin liquid, 100,000 IU/mL, dissolved in 432 mL of distilled water producing 10,000 IU nystatin/mL solution) used as an adjunct to nystatin vaginal lozenge (100,000 IU/g, dissolved in the mouth three times daily for seven days)
Study: 7773850
Drug: Antifungal denture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal denture soaking solution
Study: 1691385
Drug: Felodipine-ER 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine-ER 5 mg once daily (n = 49)
Study: 29986613
Drug: Intermittent oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent oxytocin infusion
Study: 26309128
Drug: Continued oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued oxytocin infusion
Study: 31083052
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBT) plus enhanced usual care
Study: 16421131
Drug: Active monitoring
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active monitoring (n = 69, simple tablet count and electronic monitoring)
Study: 16421131
Drug: Simple tablet
Normalized name: Monistat Simple Therapy
DrugBank: Octisalate (DB11062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simple tablet count
Study: 14738230
Drug: Theophylline (2x250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (2x250 mg x day(‐1))
Study: 14738230
Drug: Acetazolamide (2x250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (2x250 mg x day(‐1))
Study: 8996307
Drug: Dihydrocodeine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrocodeine (1 mg/kg body weight)
Study: 8097802
Drug: oral captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral captopril (n = 8)
Study: 31520460
Drug: Coblopasvir (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coblopasvir (30 or 60 mg) plus Sofosbuvir (400 mg) once daily for 12 weeks
Study: 31520460
Drug: Coblopasvir (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coblopasvir (60 mg) plus Sofosbuvir (400 mg) once daily for 12 weeks (for patients with cirrhosis)
Study: 30563215
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of vitamin D (7 drops, 1750 IU/day)
Study: 30563215
Drug: Monthly administration
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly administration of vitamin D (50,000 IU/month)
Study: 22439742
Drug: Trimodality therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimodality therapy including iodine-125 brachytherapy (125I-BT), external beam radiation therapy (EBRT), and 6-month combined androgen blockade (CAB) followed by 2 years of adjuvant hormone therapy (HT) with luteinizing hormone-releasing hormone agonist.
Study: 22439742
Drug: Trimodality therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimodality therapy including iodine-125 brachytherapy (125I-BT), external beam radiation therapy (EBRT), and 6-month combined androgen blockade (CAB) without long-term hormone therapy.
Study: 11828745
Drug: Corticosteroid creams
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid creams (Lidomex) alone
Study: 11828745
Drug: Admixture of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Admixture of Lidomex ointment and urea/heparinoid ointments
Study: 11828745
Drug: Ointments alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointments alone
Study: 6111126
Drug: Flunitrazepam (Rohypnol)
Normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (Rohypnol) 2 mg
Study: 18757088
Drug: Ivabradine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine (5 mg, with intention to increase to 7.5 mg twice a day)
Study: 15750103
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg once daily for a mean duration of 27 days (SD 12.2 days)
Study: 15750103
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for a mean duration of 27 days (SD 13.9 days)
Study: 12651918
Drug: Low-dose sodium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sodium nitroprusside (SNP) infusion during hyperthermia at Site B
Study: 12651918
Drug: Low-dose sodium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sodium nitroprusside (SNP) infusion during hyperthermia at Site C
Study: 12651918
Drug: Low-dose sodium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sodium nitroprusside (SNP) infusion during hyperthermia at Sites B and C
Study: 10961763
Drug: Cocaine hydrochloride
Normalized name: Cocaine Hydrochloride
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine hydrochloride (10% solution, 1 ml, 40-50 mg per application)
Study: 10961763
Drug: Lidocaine (10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (10% solution, 1 ml)
Study: 31775699
Drug: Vlog doing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vlog doing a challenge with fruit and vegetables (e.g., contests, tricks, games)
Study: 22683252
Drug: PF 1
Normalized name: APF 1.23% Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF 1 mg + ranibizumab (combination) Q4W
Study: 22683252
Drug: PF 1
Normalized name: APF 1.23% Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF 1 mg every 4 weeks (Q4W)
Study: 22683252
Drug: PF 3
Normalized name: Solbar Zinc SPF 38
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF 3 mg Q4W
Study: 22683252
Drug: PF 3
Normalized name: Solbar Zinc SPF 38
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF 3 mg every 2 weeks (Q2W)
Study: 22683252
Drug: PF monotherapy
Normalized name: PF-06459988
DrugBank: PF-06459988 (DB14768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF monotherapy groups
Study: 18523642
Drug: Home based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home based intervention for caregivers, including information on dementia, guidance on behaviour management, psychiatric assessment, and psychotropic medication if needed.
Study: 11994976
Drug: All-trans-retinoic acid
Normalized name: all-trans-Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans-retinoic acid (ATRA) alone (15, 45, or 75 mg/m²/day on alternate days for 21 days)
Study: 1816813
Drug: 2% epinephrine-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% epinephrine-free Articain solution (Ultracain 2%)
Study: 1816813
Drug: 4% Articain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% Articain solution with epinephrine (Ultracain D-S)
Study: 6095602
Drug: Chemotherapy (bleomycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (bleomycin, methotrexate, vincristine) before irradiation
Study: 31622159
Drug: Carbohydrate gel
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate gel ingestion
Study: 19803574
Drug: Brief motivational
Normalized name: ALCOHOL 300 mL in 375 mL TOPICAL LIQUID [Nelsons Clean Brier Tennessee Handwash]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief motivational treatment (telephone motivational interview and mailed self-help workbook)
Study: 19803574
Drug: Brief motivational
Normalized name: ALCOHOL 300 mL in 375 mL TOPICAL LIQUID [Nelsons Clean Brier Tennessee Handwash]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief motivational booster treatment (telephone motivational interview, workbook, and 6 booster calls over 9 months)
Study: 19803574
Drug: Brief booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief booster treatment
Study: 9414143
Drug: Cilostazol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (100 mg)
Study: 9414143
Drug: Theophylline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (200 mg)
Study: 30770308
Drug: Lenalidomide with
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide with dose reductions
Study: 27402596
Drug: Acute administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute administration of ghrelin
Study: 22432824
Drug: Intraligamentary injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraligamentary injection of piroxicam (0.4 mL)
Study: 22432824
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (intraligamentary injection of lidocaine, 0.4 mL)
Study: 19158153
Drug: Treatment by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment by female physicians
Study: 19158153
Drug: Treatment by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment by male physicians
Study: 17192771
Drug: 1,4-butanediol (BD)
DrugBank: 1,4-Butanediol (DB01955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,4-butanediol (BD) 25 mg/kg
Study: 15114226
Drug: Intravenous pentazocine
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pentazocine (0.5 mg/kg)
Study: 9779697
Drug: OTFC (dose-titrated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTFC (dose-titrated)
Study: 9779697
Drug: Usual breakthrough
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual breakthrough medication
Study: 3339482
Drug: Intensive education
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive education program for internal medicine residents
Study: 23241989
Drug: DTaP₅‐IPV‐Hib‐HepB with
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP₅‐IPV‐Hib‐HepB with PCV7 administered 1 month later
Study: 12868995
Drug: Basiliximab plus
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Basiliximab plus early low-dose cyclosporin
Study: 10720881
Drug: Irbesartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (150 mg/day for 8 weeks)
Study: 20182403
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection (IVT) of 4 mg triamcinolone acetonide
Study: 20182403
Drug: Subtenon infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subtenon infusion (STI) of 40 mg triamcinolone acetonide
Study: 16264062
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate dry powder inhaler (MF-DPI) 400 mug once daily in the evening
Study: 16264062
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate dry powder inhaler (MF-DPI) 200 mug twice daily
Study: 10223933
Drug: SB 209763
Normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB 209763 (10 mg/kg)
Study: 10223933
Drug: SB 209763
Normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB 209763 (various doses: 0.25, 1.25, 5.0, or 10.0 mg/kg)
Study: 10223933
Drug: SB 209763
Normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB 209763 (1.25 to 10.0 mg/kg)
Study: 25384
Drug: Antacid prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid prophylaxis (hourly titration to keep gastric pH above 3.5)
Study: 25384
Drug: Antacid medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid medication (for those who bled in control group)
Study: 30760846
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray (0.5 mL of 5% phenylephrine)
Study: 24184983
Drug: Artesunate treatment
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate treatment
Study: 28289193
Drug: Artesunate treatment
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate treatment in patients with kelch13 mutant parasites
Study: 26343840
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics for 7 days plus standard stroke unit care
Study: 19270033
Drug: Modafinil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100 mg daily for 7 days followed by 200 mg daily for 7 days)
Study: 16706692
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg orally, twice a day for 5 days (acute gout arthritis)